<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19573" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Citalopram</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharbaf Shoar</surname>
            <given-names>Nazila</given-names>
          </name>
          <aff>Ross University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fariba</surname>
            <given-names>Kamron A.</given-names>
          </name>
          <aff>University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padhy</surname>
            <given-names>Ranjit K.</given-names>
          </name>
          <aff>UCLA - Kern Medical</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nazila Sharbaf Shoar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kamron Fariba declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ranjit Padhy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19573.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Citalopram hydrobromide is a selective serotonin reuptake inhibitor. The primary FDA-approved clinical use for citalopram hydrobromide is for treating depression in adults.&#x000a0;Off-label uses include alcohol use disorder, coronary arteriosclerosis, obsessive-compulsive disorder, panic disorder, postmenopausal flushing, and premenstrual dysphoric disorder. Citalopram is listed in the WHO model list of essential medicines to treat depressive disorders. Citalopram hydrobromide exerts its&#x000a0;antidepressant action by potentiating serotonergic activity in the central nervous system. Multiple studies confirmed that citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) that has minimal effects on norepinephrine and dopamine neuronal reuptake. This activity reviews the indications, mechanism of action, administration, contraindications, monitoring, toxicity associated with citalopram, and the interprofessional team's role in caring for patients with conditions treated&#x000a0;with citalopram.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the FDA-approved and off-label indications for citalopram.</p></list-item><list-item><p>Apply evidence-based guidelines and recommendations when selecting citalopram as a treatment option.</p></list-item><list-item><p>Assess patients for potential adverse effects associated with citalopram.</p></list-item><list-item><p>Collaborate with mental health specialists, pharmacists, and other healthcare team members to optimize citalopram therapy and ensure the best outcomes with minimal adverse events.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19573&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19573">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19573.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Citalopram hydrobromide, the&#x000a0;most selective serotonin reuptake inhibitor (SSRI), received FDA approval in 1998.<xref ref-type="bibr" rid="article-19573.r1">[1]</xref>&#x000a0;Citalopram&#x000a0;is listed in the WHO model list of essential medicines to treat depressive disorders. According to the 2022 NICE (National Institute for Health and Care Excellence)&#x000a0;guidelines, SSRIs should be considered&#x000a0;the&#x000a0;initial choice for&#x000a0;pharmacotherapy in patients with depression.<xref ref-type="bibr" rid="article-19573.r2">[2]</xref></p>
        <p>
<bold>FDA-Approved Indication</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Citalopram hydrobromide is for the treatment of depression in&#x000a0;adults 18 years or older<xref ref-type="bibr" rid="article-19573.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Recommendation: Adult, class IIa</p>
          </list-item>
          <list-item>
            <p>Strength of evidence: Adult, category B</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Use</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Obsessive-compulsive disorder (OCD)<xref ref-type="bibr" rid="article-19573.r4">[4]</xref><xref ref-type="bibr" rid="article-19573.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Panic disorder<xref ref-type="bibr" rid="article-19573.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Generalized anxiety disorder (GAD)<xref ref-type="bibr" rid="article-19573.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Social anxiety disorder (SAD)</p>
          </list-item>
          <list-item>
            <p>Separation anxiety disorder</p>
          </list-item>
          <list-item>
            <p>Premenstrual dysphoric disorder (PMDD)<xref ref-type="bibr" rid="article-19573.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Binge eating disorder<xref ref-type="bibr" rid="article-19573.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Posttraumatic stress disorder (PTSD)<xref ref-type="bibr" rid="article-19573.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Premature ejaculation<xref ref-type="bibr" rid="article-19573.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Poststroke depression<xref ref-type="bibr" rid="article-19573.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>The advantages and disadvantages of off-label use of this drug depend on the patient's condition and the clinician's judgment.</p>
      </sec>
      <sec id="article-19573.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Citalopram hydrobromide exerts its&#x000a0;antidepressant action by potentiating serotonergic activity in the central nervous system (CNS). Multiple studies confirm that citalopram hydrobromide, an SSRI, has minimal effects on norepinephrine and dopamine neuronal reuptake.<xref ref-type="bibr" rid="article-19573.r13">[13]</xref>&#x000a0;The drug has a low affinity for muscarinic acetylcholine receptors and mild antagonist action&#x000a0;on histamine but no significant effect on alpha- or beta-adrenergic receptors or dopamine-1, dopamine-2, gamma-aminobutyric acid, opioid, or benzodiazepine receptors.<xref ref-type="bibr" rid="article-19573.r14">[14]</xref><xref ref-type="bibr" rid="article-19573.r15">[15]</xref> Citalopram is a racemic mixture of both <italic toggle="yes">(R)-</italic> and <italic toggle="yes">(S)-</italic>enantiomers, whereas escitalopram consists solely of the <italic toggle="yes">(S)-</italic>enantiomer.<xref ref-type="bibr" rid="article-19573.r16">[16]</xref></p>
        <p>The neurotrophic hypothesis of depression emphasizes that depression results from reduced brain-derived neurotrophic factor (BDNF), leading to neuronal loss and reduced&#x000a0;hippocampal neurogenesis. Antidepressants elevate BDNF levels, counteracting neuronal and cellular loss. Extensive research in both preclinical and clinical depression studies reveals reduced serum BDNF levels in depressed individuals. Antidepressants, including citalopram, raise the expression of BDNF in the hippocampus and&#x000a0;preferential cortex.<xref ref-type="bibr" rid="article-19573.r17">[17]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The onset of action for depression is about 1 to 4 weeks. However, the complete response may take 8 to 12 weeks after treatment initiation.</p>
          </list-item>
          <list-item>
            <p>Bioavailability is 80%. Tablets and oral solutions are bioequivalent.</p>
          </list-item>
          <list-item>
            <p>Half-life is 24 to 48 hours (average, 35 hours). However, in patients with hepatic impairment, mild-to-moderate renal impairment, older age (60 or older), and those who are poor CYP2C19 metabolizers, the drug's half-life notably extends.</p>
          </list-item>
          <list-item>
            <p>Citalopram is metabolized primarily by CYP450 3A4 and 2C19, and it exhibits weak inhibitory effects on CYP450 2D6.<xref ref-type="bibr" rid="article-19573.r18">[18]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19573.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Citalopram is available in multiple oral dosage forms, including 10 mg, 20 mg, and 40 mg tablets taken once daily, as well as an oral solution with a concentration of 10 mg/5 mL. It is typically administered orally&#x000a0;for adult patients&#x000a0;younger than 60.</p>
        <list list-type="bullet">
          <list-item>
            <p>An initial dosage of 20 mg once daily (morning or evening, with or without food)</p>
          </list-item>
          <list-item>
            <p>Increase the dosage to 40 mg daily after one week (maximum dosage of 40 mg daily)</p>
          </list-item>
          <list-item>
            <p>The maximum dosage is 20 mg daily for patients older than 60 or those who are poor metabolizers of CYP2C19.</p>
          </list-item>
        </list>
        <p>Patients who are at risk of experiencing significant adverse effects or overstimulation with citalopram should be started with the lowest recommended dosage. The dose should be increased gradually in 10-mg increments to optimize therapy. Anecdotal reports propose potential benefits of higher citalopram doses for individuals with OCD. Nevertheless, caution is advised, as dosages surpassing 40 mg daily are not recommended due to the associated risk of QT prolongation.<xref ref-type="bibr" rid="article-19573.r19">[19]</xref><xref ref-type="bibr" rid="article-19573.r20">[20]</xref><xref ref-type="bibr" rid="article-19573.r21">[21]</xref></p>
        <p>
<bold>Specific Population</bold>
</p>
        <p><bold>Hepatic impairment:</bold> According to product labeling, the dosage needs to be reduced to 20 mg daily for patients with hepatic impairment.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;No dose adjustment is&#x000a0;necessary for patients with mild-to-moderate renal impairment.&#x000a0;Patients with severe renal impairments should be closely monitored for possible adverse reactions.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Citalopram&#x000a0;is an FDA pregnancy category C drug. Citalopram is not an absolute contraindication in pregnancy but is not generally recommended, especially during the first trimester. Clinicians treating women with psychiatric conditions must inform the patient whether these medicines are needed during pregnancy.<xref ref-type="bibr" rid="article-19573.r22">[22]</xref>&#x000a0;Some reports associate SSRIs with persistent pulmonary hypertension of the newborn (PPHN).<xref ref-type="bibr" rid="article-19573.r23">[23]</xref><xref ref-type="bibr" rid="article-19573.r24">[24]</xref>&#x000a0;Manufacturers report neonates exposed to&#x000a0;SSRIs or SNRIs late in the third trimester have developed complications requiring&#x000a0;respiratory support,&#x000a0;tube feeding, and prolonged hospitalization.</p>
        <p><bold>Breastfeeding considerations:</bold> Based on the safety scoring system, citalopram is considered acceptable for use during breastfeeding. In cases where the mother used citalopram during pregnancy or other psychotropic drugs have proven ineffective, most experts typically advise against switching medications while breastfeeding. Drugs with lower excretion into breast milk are generally preferred, especially while nursing preterm infants or newborns. Breastfed newborns should be monitored for&#x000a0;poor feeding, excess drowsiness, restlessness, agitation, and poor weight gain. Extra care should be exercised in a younger and exclusively breastfed infant when a breastfeeding woman is on psychotropic drugs.<xref ref-type="bibr" rid="article-19573.r25">[25]</xref></p>
        <p><bold>Pediatric patients:</bold> According to the package insert, the drug is not approved for use in pediatric patients, although clinicians may use it off-label for major depressive disorder, generalized anxiety disorder, and OCD.</p>
        <p><bold>Older patients: </bold>Citalopram has been listed in the Beers Criteria (American Geriatric Society) as a potentially inappropriate medicine.&#x000a0;Caution&#x000a0;should be used in patients aged 65 and older as it can cause or worsen hyponatremia or syndrome of inappropriate antidiuretic hormone secretion (SIADH).<xref ref-type="bibr" rid="article-19573.r26">[26]</xref></p>
      </sec>
      <sec id="article-19573.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Reports suggest that adverse reactions occur in up to 10% of patients.<xref ref-type="bibr" rid="article-19573.r4">[4]</xref><xref ref-type="bibr" rid="article-19573.r27">[27]</xref><xref ref-type="bibr" rid="article-19573.r28">[28]</xref></p>
        <p>
<bold>Most Common Adverse Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CNS: Drowsiness, insomnia, dizziness, headache (dose-dependent)</p>
          </list-item>
          <list-item>
            <p>Dermatologic: Diaphoresis</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal: Nausea, vomiting, xerostomia, constipation, diarrhea</p>
          </list-item>
          <list-item>
            <p>Sexual: Ejaculation disorder (dose-dependent)<xref ref-type="bibr" rid="article-19573.r29">[29]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Less Common Adverse Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiovascular: Myocardial infarction, prolonged QT interval, Torsades de pointes</p>
          </list-item>
          <list-item>
            <p>Hematologic: Hemorrhage, abnormal</p>
          </list-item>
          <list-item>
            <p>Neurologic: Cerebrovascular accident</p>
          </list-item>
          <list-item>
            <p>Psychiatric: Suicidal ideation, suicide, induction of mania<xref ref-type="bibr" rid="article-19573.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Other: Serotonin syndrome&#x000a0;<xref ref-type="bibr" rid="article-19573.r31">[31]</xref></p>
          </list-item>
        </list>
        <p>Hyponatremia resulting from SIADH is a rare adverse effect. Citalopram has been shown to&#x000a0;induce hyponatremia in case reports involving&#x000a0;older patients. In addition to advanced age, other factors such as female gender, concurrent diuretic use, low body weight, and recent pneumonia may increase the likelihood of hyponatremia.</p>
        <p>Evidence indicates a direct correlation between the dosage and the severity of adverse effects such as impotence, fatigue, somnolence, insomnia, sweating, and yawning.</p>
        <p>
<bold>Abrupt Discontinuation of Antidepressant</bold>
</p>
        <p>Antidepressant discontinuation syndrome commonly results when patients suddenly stop antidepressant therapy. The most common discontinuation syndrome symptoms include nausea, vomiting, diarrhea, headaches, light-headedness, dizziness, diminished appetite, sweating, chills, tremors, fatigue, somnolence, and sleep disturbances. Less common symptoms include electric shock-like sensations, cardiac arrhythmias, myalgia, arthralgia, and balance difficulties. Due to these&#x000a0;adverse effects, gradual tapering of the antidepressant therapy over several weeks to several months (based on the treatment duration) is strongly recommended. The half-life of drugs and duration of the therapy should factor in these decisions, as antidepressants with a shorter half-life may need to be tapered more conservatively.</p>
        <p>
<bold>
<bold>Boxed Warning</bold>
</bold>
</p>
        <p>Citalopram hydrobromide&#x000a0;is correlated with suicidality and worsening depression, especially in children, adolescents, and young adults (younger than 24). Antidepressants may elevate the risk of suicidal ideation in children, adolescents, and young adults when compared to placebo administration. The decision to use citalopram hydrobromide or any other antidepressant in children through young adults depends on the patient's specific condition and the clinician's judgment, weighing the potential benefits and risks on a case-by-case basis.<xref ref-type="bibr" rid="article-19573.r32">[32]</xref></p>
        <p>Patients of any age who start antidepressant therapy should be monitored and observed closely for clinical deterioration, suicidality, or unusual behavior changes. Citalopram hydrobromide is not FDA-approved for use in&#x000a0;pediatric patients.</p>
        <p>Increased risk of suicidal ideation and treatment-emergent suicidal ideation (TESI)&#x000a0;are concerns in younger patients at the onset of therapy. However, an analysis of 17 controlled clinical trials comprising 5000 patients who were treated with citalopram, a tricyclic antidepressant, another SSRI, or a placebo revealed that the citalopram group had the lowest incidence of suicide. Furthermore, family and twin studies offer evidence of a genetic influence on suicidal behavior, leading to the hypothesis that genetic factors may also contribute to TESI.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Citalopram has significant drug interactions, and clinicians should monitor patients closely. Limit the dosage of citalopram to a maximum of 20 mg per day if the patient is using bupropion, omeprazole, esomeprazole, cimetidine, fexinidazole, voriconazole, fluoxetine, fluvoxamine, or fluconazole.<bold>&#x000a0;</bold>Citalopram is a substrate for CYP2C19, while fluconazole inhibits CYP2C19, potentially resulting in serotonin toxicity.<xref ref-type="bibr" rid="article-19573.r33">[33]</xref></p>
        <p>SSRIs, including citalopram, may increase the risk of bleeding. SSRIs inhibit the serotonin transporter responsible for serotonin uptake into platelets. Consequently, SSRIs can deplete platelet serotonin, decreasing the ability to form clots and increasing the risk of bleeding.&#x000a0;In addition, concurrent use of aspirin, NSAIDs, and warfarin increases the risk of bleeding.<xref ref-type="bibr" rid="article-19573.r34">[34]</xref><xref ref-type="bibr" rid="article-19573.r35">[35]</xref></p>
      </sec>
      <sec id="article-19573.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Citalopram is contraindicated with the concomitant use&#x000a0;of monoamine oxidase inhibitors (MAOIs). Evidence suggests that concurrent use of citalopram alongside an MAOI can result in serotonin syndrome (serotonergic hyperactivity). Symptoms of serotonin syndrome include rigidity, hyperthermia, autonomic instability, mental status changes, and coma. Similar adverse reactions are possible in patients who abruptly switched from an SSRI to an MAOI; therefore, the recommendation is to wait 14 days after discontinuing citalopram to initiate an MAOI.<xref ref-type="bibr" rid="article-19573.r36">[36]</xref></p>
        <p>Citalopram is also contraindicated in patients with hypersensitivity to the drug or excipient.<xref ref-type="bibr" rid="article-19573.r37">[37]</xref>&#x000a0;Secondary to its inhibitory effects on CYP 2D6, it could hypothetically increase thioridazine concentrations, inducing dangerous arrhythmias.<xref ref-type="bibr" rid="article-19573.r38">[38]</xref> Canadian labeling for citalopram includes additional contraindications, specifically mentioning known QT interval prolongation or congenital long QT syndrome, which are not listed in the United States labeling.<xref ref-type="bibr" rid="article-19573.r39">[39]</xref>&#x000a0;Citalopram should not be administered in patients using urokinase, pimozide, methylene blue, linezolid, or dapoxetine. Linezolid is a&#x000a0;reversible, nonselective monoamine oxidase inhibitor that can lead to serotonin syndrome if administered with serotonergic drugs.<xref ref-type="bibr" rid="article-19573.r40">[40]</xref><xref ref-type="bibr" rid="article-19573.r41">[41]</xref></p>
      </sec>
      <sec id="article-19573.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>
<bold>Before Treatment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Electrolytes, especially potassium and sodium,&#x000a0;should be monitored and evaluated. Reevaluating electrolytes in patients at risk for electrolyte disturbances during the treatment is recommended.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>QT-prolongation should be monitored. ECG is necessary for patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, uncompensated heart failure, or concomitant use of other QT-prolonging drugs.<xref ref-type="bibr" rid="article-19573.r42">[42]</xref></p>
          </list-item>
        </list>
        <p>
<bold>During Treatment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients need to be assessed and monitored for worsening depression, suicidality, or unusual changes in behavior during the initial few months of therapy or when the dose increases or decreases. Weekly face-to-face contact with patients during the initial&#x000a0;first month of treatment,&#x000a0;followed by visits every other week for the next month and ultimately&#x000a0;at 3-month intervals, is recommended.</p>
          </list-item>
          <list-item>
            <p>Weight and growth should be monitored regularly by a clinician during treatment in children and adolescents.</p>
          </list-item>
          <list-item>
            <p>According to the Beers Criteria, monitor sodium levels closely when starting or adjusting the dose of citalopram in patients aged 65 and older.<xref ref-type="bibr" rid="article-19573.r26">[26]</xref><xref ref-type="bibr" rid="article-19573.r26">[26]</xref></p>
          </list-item>
        </list>
        <p><bold>Psychiatric Assessment</bold>&#x000a0;<bold>for Depression and Anxiety</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Various scales in clinical practice can assist in screening anxiety disorder and depression and response to citalopram therapy. &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patient Health Questionnaire (PHQ-9)<xref ref-type="bibr" rid="article-19573.r43">[43]</xref>&#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Montgomery-Asberg Depression Rating Scale(MADRS)<xref ref-type="bibr" rid="article-19573.r44">[44]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hamilton Rating Scale for Depression(HDRS-17)<xref ref-type="bibr" rid="article-19573.r45">[45]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Generalized Anxiety Disorder 7 score (GAD-7)<xref ref-type="bibr" rid="article-19573.r46">[46]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hamilton Anxiety Scale (HAM-A)<xref ref-type="bibr" rid="article-19573.r47">[47]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19573.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Studies reveal that citalopram toxicity is not common, even at doses up to 100 mg. However, there is a chance&#x000a0;of developing serotonin&#x000a0;hyperactivity&#x000a0;at therapeutic doses, primarily if using another serotonergic medication concomitantly.&#x000a0;</p>
        <p>In the event of an intentional overdose, the ingestion of more than 600 mg of citalopram requires 8 hours of cardiac monitoring. At the end of the observation period, the patient can be discharged if the patient is asymptomatic and QTc is less than 450 milliseconds. However, continued inpatient cardiac monitoring is necessary for patients with QTc greater than 450 milliseconds at the end of the observation period.<xref ref-type="bibr" rid="article-19573.r48">[48]</xref>&#x000a0;Case reports also describe recurrent seizures associated with massive citalopram overdose. Seizures should be treated with benzodiazepines.<xref ref-type="bibr" rid="article-19573.r49">[49]</xref></p>
        <p>Management of&#x000a0;serotonin syndrome requires&#x000a0;withdrawal of the citalopram&#x000a0;and aggressive supportive treatment&#x000a0;for hyperthermia and autonomic dysfunction. Cyproheptadine, a serotonin antagonist (5HT2 receptors),&#x000a0;can be administered.<xref ref-type="bibr" rid="article-19573.r50">[50]</xref></p>
      </sec>
      <sec id="article-19573.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Citalopram hydrobromide is a widely prescribed antidepressant by nurse practitioners, primary care providers, psychiatrists, internists, and neurologists. While the drug is effective for depression, its use requires monitoring. Prescribers should be careful as citalopram correlates with suicidality and worsening depression, especially in children, adolescents, and young adults (younger than 24 years old). Also, clinicians should monitor electrolytes and obtain an ECG before starting treatment because of the risk of prolonged QT syndrome. Nurses and pharmacists should counsel and educate patients not to combine the drug with alcohol, sedatives, and other antidepressants.</p>
        <p>In an overdose, the rapid response team and the emergency clinician should rapidly stabilize the patient. Thus, an interprofessional approach that includes clinicians&#x000a0;and pharmacists who operate as an integrated team with open communication is optimal for employing citalopram therapy, resulting in better patient outcomes with fewer adverse events.&#x000a0;</p>
      </sec>
      <sec id="article-19573.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19573&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19573">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19573/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19573">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19573.s11">
        <title>References</title>
        <ref id="article-19573.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lochmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Selective Serotonin Reuptake Inhibitors.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2019</year>
            <volume>250</volume>
            <fpage>135</fpage>
            <page-range>135-144</page-range>
            <pub-id pub-id-type="pmid">30838457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kendrick</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pilling</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mavranezouli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Megnin-Viggars</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ruane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eadon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>N</given-names>
              </name>
              <collab>Guideline Committee</collab>
            </person-group>
            <article-title>Management of depression in adults: summary of updated NICE guidance.</article-title>
            <source>BMJ</source>
            <year>2022</year>
            <month>Jul</month>
            <day>20</day>
            <volume>378</volume>
            <fpage>o1557</fpage>
            <pub-id pub-id-type="pmid">35858703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cipriani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Purgato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Trespidi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Imperadore</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Signoretti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Churchill</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barbui</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Citalopram versus other anti-depressive agents for depression.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2012</year>
            <month>Jul</month>
            <day>11</day>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>CD006534</fpage>
            <pub-id pub-id-type="pmid">22786497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bezchlibnyk-Butler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aleksic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Citalopram--a review of pharmacological and clinical effects.</article-title>
            <source>J Psychiatry Neurosci</source>
            <year>2000</year>
            <month>May</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>241</fpage>
            <page-range>241-54</page-range>
            <pub-id pub-id-type="pmid">10863884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomsen</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>1997</year>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>157</fpage>
            <page-range>157-66</page-range>
            <pub-id pub-id-type="pmid">9466233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bertani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caldirola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smeraldi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bellodi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study.</article-title>
            <source>Pharmacopsychiatry</source>
            <year>2001</year>
            <month>May</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>85</fpage>
            <page-range>85-90</page-range>
            <pub-id pub-id-type="pmid">11434404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varia</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rauscher</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Treatment of generalized anxiety disorder with citalopram.</article-title>
            <source>Int Clin Psychopharmacol</source>
            <year>2002</year>
            <month>May</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>103</fpage>
            <page-range>103-7</page-range>
            <pub-id pub-id-type="pmid">11981350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nevatte</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>B&#x000e4;ckstr&#x000f6;m</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dennerstein</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Endicott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Epperson</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Halbreich</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Panay</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pearlstein</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rapkin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rubinow</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Studd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sundstr&#x000f6;m-Poromaa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yonkers</surname>
                <given-names>K</given-names>
              </name>
              <collab>Consensus Group of the International Society for Premenstrual Disorders</collab>
            </person-group>
            <article-title>ISPMD consensus on the management of premenstrual disorders.</article-title>
            <source>Arch Womens Ment Health</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>279</fpage>
            <page-range>279-91</page-range>
            <pub-id pub-id-type="pmid">23624686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McElroy</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Welge</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Keck</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>64</volume>
            <issue>7</issue>
            <fpage>807</fpage>
            <page-range>807-13</page-range>
            <pub-id pub-id-type="pmid">12934982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>English</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Jewell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jewell</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ambrose</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Treatment of chronic posttraumatic stress disorder in combat veterans with citalopram: an open trial.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-8</page-range>
            <pub-id pub-id-type="pmid">16415713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saleh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Majzoub</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abu El-Hamd</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>An update on the treatment of premature ejaculation: A systematic review.</article-title>
            <source>Arab J Urol</source>
            <year>2021</year>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>281</fpage>
            <page-range>281-302</page-range>
            <pub-id pub-id-type="pmid">34552780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Towfighi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>El Husseini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hackett</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Jorge</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Kissela</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Skolarus</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Whooley</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>LS</given-names>
              </name>
              <collab>American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research</collab>
            </person-group>
            <article-title>Poststroke Depression: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.</article-title>
            <source>Stroke</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>e30</fpage>
            <page-range>e30-e43</page-range>
            <pub-id pub-id-type="pmid">27932603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chaimani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kataoka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ostinelli</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cipriani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salanti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Evidence synthesis, practice guidelines and real-world prescriptions of new generation antidepressants in the treatment of depression: a protocol for cumulative network meta-analyses and meta-epidemiological study.</article-title>
            <source>BMJ Open</source>
            <year>2018</year>
            <month>Dec</month>
            <day>09</day>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>e023222</fpage>
            <pub-id pub-id-type="pmid">30530583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hyttel</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity.</article-title>
            <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
            <year>1982</year>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>277</fpage>
            <page-range>277-95</page-range>
            <pub-id pub-id-type="pmid">6128769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baumann</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1996</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>444</fpage>
            <page-range>444-69</page-range>
            <pub-id pub-id-type="pmid">8968657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edinoff</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Akuly</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Ochoa</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Patti</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Ghaffar</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Viswanath</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Urits</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review.</article-title>
            <source>Neurol Int</source>
            <year>2021</year>
            <month>Aug</month>
            <day>05</day>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>387</fpage>
            <page-range>387-401</page-range>
            <pub-id pub-id-type="pmid">34449705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chakrapani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eskander</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>De Los Santos</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Omisore</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Mostafa</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Neuroplasticity and the Biological Role of Brain Derived Neurotrophic Factor in the Pathophysiology and Management of Depression.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Nov</month>
            <day>09</day>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>e11396</fpage>
            <pub-id pub-id-type="pmid">33312794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ji</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Schaid</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Desta</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kubo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Batzler</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mushiroda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kamatani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ogburn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hall-Flavin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Flockhart</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mrazek</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Weinshilboum</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>373</fpage>
            <page-range>373-83</page-range>
            <pub-id pub-id-type="pmid">24528284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wagner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>L&#x000f6;hrs</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Siskind</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Honer</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Falkai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance.</article-title>
            <source>J Psychopharmacol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>423</fpage>
            <page-range>423-435</page-range>
            <pub-id pub-id-type="pmid">30696332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <chapter-title>Escitalopram</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>4</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30000334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alu&#x00161;&#x000ed;k</surname>
                <given-names>&#x00160;</given-names>
              </name>
              <name>
                <surname>Paluch</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>[Citalopram and QT prolongation].</article-title>
            <source>Vnitr Lek</source>
            <year>2018</year>
            <season>Winter</season>
            <volume>63</volume>
            <issue>12</issue>
            <fpage>952</fpage>
            <page-range>952-956</page-range>
            <pub-id pub-id-type="pmid">29334745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larsen</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Damkier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Fenger-Gron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mikkelsen</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Skaarup</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Videbech</surname>
                <given-names>P</given-names>
              </name>
              <collab>Danish Psychiatric Society</collab>
              <collab>Danish Society of Obstetrics and Gynecology</collab>
              <collab>Danish Paediatric Society</collab>
              <collab>Danish Society of Clinical Pharmacology</collab>
            </person-group>
            <article-title>Use of psychotropic drugs during pregnancy and breast-feeding.</article-title>
            <source>Acta Psychiatr Scand Suppl</source>
            <year>2015</year>
            <issue>445</issue>
            <fpage>1</fpage>
            <page-range>1-28</page-range>
            <pub-id pub-id-type="pmid">26344706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munk-Olsen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bergink</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rommel</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Momen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Association of Persistent Pulmonary Hypertension in Infants With the Timing and Type of Antidepressants In Utero.</article-title>
            <source>JAMA Netw Open</source>
            <year>2021</year>
            <month>Dec</month>
            <day>01</day>
            <volume>4</volume>
            <issue>12</issue>
            <fpage>e2136639</fpage>
            <pub-id pub-id-type="pmid">34851402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Temming</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Clinical management of medications in pregnancy and&#x000a0;lactation.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>214</volume>
            <issue>6</issue>
            <fpage>698</fpage>
            <page-range>698-702</page-range>
            <pub-id pub-id-type="pmid">26844758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <chapter-title>Citalopram</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hekmatjah</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tareen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tareen</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Citalopram-Associated Alopecia: A Case Report and Brief Literature Review.</article-title>
            <source>Curr Drug Saf</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-170</page-range>
            <pub-id pub-id-type="pmid">30767750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aboukarr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giudice</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors.</article-title>
            <source>Can J Hosp Pharm</source>
            <year>2018</year>
            <season>May-Jun</season>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>196</fpage>
            <page-range>196-207</page-range>
            <pub-id pub-id-type="pmid">29955193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milne</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Goa</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.</article-title>
            <source>Drugs</source>
            <year>1991</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>450</fpage>
            <page-range>450-77</page-range>
            <pub-id pub-id-type="pmid">1711447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beckwith</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>The precipitation of mania by citalopram in a patient with interferon-induced depression.</article-title>
            <source>Psychosomatics</source>
            <year>2008</year>
            <season>Jul-Aug</season>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>362</fpage>
            <page-range>362-3</page-range>
            <pub-id pub-id-type="pmid">18621943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schult</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Picard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wiegand</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Citalopram overdose and severe serotonin syndrome in an intermediate metabolizing patient.</article-title>
            <source>Am J Emerg Med</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>1993.e5</fpage>
            <page-range>1993.e5-1993.e6</page-range>
            <pub-id pub-id-type="pmid">31257122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahikainen</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Vauhkonen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pett</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Palo</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Haukka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ojanper&#x000e4;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Niemi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sajantila</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Completed suicides of citalopram users-the role of CYP genotypes and adverse drug interactions.</article-title>
            <source>Int J Legal Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>133</volume>
            <issue>2</issue>
            <fpage>353</fpage>
            <page-range>353-363</page-range>
            <pub-id pub-id-type="pmid">30173302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levin</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Cortes-Ladino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palomba</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion.</article-title>
            <source>Gen Hosp Psychiatry</source>
            <year>2008</year>
            <season>Jul-Aug</season>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>372</fpage>
            <page-range>372-7</page-range>
            <pub-id pub-id-type="pmid">18585543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferrier</surname>
                <given-names>IN</given-names>
              </name>
            </person-group>
            <article-title>SSRIs and gastrointestinal bleeding.</article-title>
            <source>BMJ</source>
            <year>2005</year>
            <month>Sep</month>
            <day>10</day>
            <volume>331</volume>
            <issue>7516</issue>
            <fpage>529</fpage>
            <page-range>529-30</page-range>
            <pub-id pub-id-type="pmid">16150746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeiss</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Connemann</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;nfeldt-Lecuona</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gahr</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Risk of Bleeding Associated With Antidepressants: Impact of Causality Assessment and Competition Bias on Signal Detection.</article-title>
            <source>Front Psychiatry</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>727687</fpage>
            <pub-id pub-id-type="pmid">34744821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferguson</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>SSRI Antidepressant Medications: Adverse Effects and Tolerability.</article-title>
            <source>Prim Care Companion J Clin Psychiatry</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-27</page-range>
            <pub-id pub-id-type="pmid">15014625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herstowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Komorowska</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cuba&#x00142;a</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Jakuszkowiak-Wojten</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ga&#x00142;uszko-W&#x00119;gielnik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Landowski</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Severe skin complications in patients treated with antidepressants: a literature review.</article-title>
            <source>Postepy Dermatol Alergol</source>
            <year>2014</year>
            <month>May</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>92</fpage>
            <page-range>92-7</page-range>
            <pub-id pub-id-type="pmid">25097474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beach</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Celano</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Noseworthy</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Huffman</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>QTc prolongation, torsades de pointes, and psychotropic medications.</article-title>
            <source>Psychosomatics</source>
            <year>2013</year>
            <season>Jan-Feb</season>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-13</page-range>
            <pub-id pub-id-type="pmid">23295003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alweis</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Long QT Syndrome: A Comprehensive Review of the Literature and Current Evidence.</article-title>
            <source>Curr Probl Cardiol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>92</fpage>
            <page-range>92-106</page-range>
            <pub-id pub-id-type="pmid">29784533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gatti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raschi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Ponti</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>233</fpage>
            <page-range>233-239</page-range>
            <pub-id pub-id-type="pmid">32901348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alotaibi</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Yousuf</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alshammari</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Late Presentation of Linezolid-Induced Serotonin Syndrome After Maprotiline and Mirtazapine Therapy: A Case Report.</article-title>
            <source>Clin Neuropharmacol</source>
            <string-date>2021 Mar-Apr 01</string-date>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>71</fpage>
            <page-range>71-74</page-range>
            <pub-id pub-id-type="pmid">33443942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montgomery</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Lyby</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Connor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tangh&#x000f8;j</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression.</article-title>
            <source>Int Clin Psychopharmacol</source>
            <year>1992</year>
            <month>Jun</month>
            <volume>6 Suppl 5</volume>
            <fpage>65</fpage>
            <page-range>65-70</page-range>
            <pub-id pub-id-type="pmid">1431024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Byng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Use of the Patient Health Questionnaire (PHQ-9) in Practice: Interactions between patients and physicians.</article-title>
            <source>Qual Health Res</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>13</issue>
            <fpage>2146</fpage>
            <page-range>2146-2159</page-range>
            <pub-id pub-id-type="pmid">32564676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hengartner</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Jakobsen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pl&#x000f6;derl</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials.</article-title>
            <source>PLoS One</source>
            <year>2020</year>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>e0229381</fpage>
            <pub-id pub-id-type="pmid">32101579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bobo</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Angler&#x000f3;</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hall-Flavin</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Weinshilboum</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Biernacka</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data.</article-title>
            <source>Hum Psychopharmacol</source>
            <year>2016</year>
            <month>May</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>185</fpage>
            <page-range>185-92</page-range>
            <pub-id pub-id-type="pmid">26999588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Haigh</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Fresco</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Using the GAD-Q-IV to identify generalized anxiety disorder in psychiatric treatment seeking and primary care medical samples.</article-title>
            <source>J Anxiety Disord</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-30</page-range>
            <pub-id pub-id-type="pmid">24334213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ahokas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jarema</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Ameringen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vavrusova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>H&#x004e7;schl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bitter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mosolov</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Olivier</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Matharan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Picarel-Blanchot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>de Bodinat</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50&#x0202f;mg/day) versus escitalopram (10-20&#x0202f;mg/day) in out-patients with severe generalized anxiety disorder.</article-title>
            <source>Eur Neuropsychopharmacol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>970</fpage>
            <page-range>970-979</page-range>
            <pub-id pub-id-type="pmid">30135032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macaluso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Preskorn</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing.</article-title>
            <source>J Psychiatr Pract</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>416</fpage>
            <page-range>416-419</page-range>
            <pub-id pub-id-type="pmid">30395549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zoofaghari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kiarasi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gheshlaghi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Massive Citalopram Overdose Associated with Recurrent Seizures and Bilateral Shoulder Dislocations.</article-title>
            <source>J Res Pharm Pract</source>
            <year>2020</year>
            <season>Jul-Sep</season>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-164</page-range>
            <pub-id pub-id-type="pmid">33489987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19573.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iqbal</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Basil</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Overview of serotonin syndrome.</article-title>
            <source>Ann Clin Psychiatry</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>310</fpage>
            <page-range>310-8</page-range>
            <pub-id pub-id-type="pmid">23145389</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
